Polarean designs and manufactures equipment for production of hyperpolarized xenon or helium gas.
When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Current investigational uses include identifying early diagnoses of respiratory diseases as well as monitoring progression and therapeutic response. In addition, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
Polarean hyperpolarization systems are currently sold in the United States and internationally for research and investigational applications only.
Polarean Imaging to start key clinical trials next month after pilot study success
Polarean Imaging seeks to raise $4.3M in IPO on London Exchange